Lava Therapeutics Nv Reports Results For The Quarter Ended In December: Earnings Summary

LAVA Therapeutics NV

11/04/2023 14:31

* LAVA Therapeutics NV  LVTX.OQ  reported a quarterly
adjusted
loss of 57 cents​​ per share for the quarter ended in December.
The mean expectation of four analysts for the quarter was for a
loss of 63 cents per share.
    * Revenue rose 164% to $2.64 million from a year ago;
analysts
expected $250.00 thousand. 
    * LAVA Therapeutics NV's reported EPS for the quarter was a
loss
of 57 cents​.
    * The mean earnings estimate of analysts had fallen by
about 4.4%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * LAVA Therapeutics NV shares had fallen by 15.7% this
quarter and
lost 60.0% so far this year.
    * The company reported a quarterly loss of $15 million.
    * Wall Street's median 12-month price target for LAVA
Therapeutics
NV is $15.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 5 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
April 11 at 01:31 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.63          -0.57          Beat
 Sep. 30 2022      -0.14          0.04           Beat
 Jun. 30 2022      -0.63          -0.31          Beat
 Mar. 31 2022      -0.86          -0.41          Beat